Xbrane Biopharma AB (publ) reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported sales was SEK 66.89 million compared to SEK 17.31 million a year ago. Net loss was SEK 157.53 million compared to SEK 60.73 million a year ago.

Basic loss per share from continuing operations was SEK 3.11 compared to SEK 2.05 a year ago. Diluted loss per share from continuing operations was SEK 3.11 compared to SEK 2.05 a year ago. Basic loss per share was SEK 5.28 compared to SEK 2.25 a year ago.

Diluted loss per share was SEK 5.28 compared to SEK 2.25 a year ago.